3/12
08:02 am
zvra
Zevra Therapeutics, Inc. (NASDAQ: ZVRA) is now covered by analysts at William Blair. They set an "outperform" rating on the stock.
Low
Report
Zevra Therapeutics, Inc. (NASDAQ: ZVRA) is now covered by analysts at William Blair. They set an "outperform" rating on the stock.
3/12
08:02 am
zvra
Zevra Therapeutics, Inc. (NASDAQ: ZVRA) is now covered by analysts at William Blair. They set an "outperform" rating on the stock.
Low
Report
Zevra Therapeutics, Inc. (NASDAQ: ZVRA) is now covered by analysts at William Blair. They set an "outperform" rating on the stock.
3/12
07:41 am
zvra
Rating for ZVRA
Low
Report
Rating for ZVRA
3/12
07:41 am
zvra
Rating for ZVRA
Low
Report
Rating for ZVRA
3/12
07:13 am
zvra
Zevra initiated with Outperform into transformational 2024 at William Blair
Low
Report
Zevra initiated with Outperform into transformational 2024 at William Blair
3/12
07:13 am
zvra
Zevra initiated with Outperform into transformational 2024 at William Blair
Low
Report
Zevra initiated with Outperform into transformational 2024 at William Blair
3/12
06:07 am
zvra
Zevra Therapeutics initiated with bullish view at William Blair
Low
Report
Zevra Therapeutics initiated with bullish view at William Blair
3/12
06:07 am
zvra
Zevra Therapeutics initiated with bullish view at William Blair
Low
Report
Zevra Therapeutics initiated with bullish view at William Blair
3/5
08:15 am
zvra
Zevra Therapeutics, Inc. (NASDAQ: ZVRA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
Medium
Report
Zevra Therapeutics, Inc. (NASDAQ: ZVRA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
1/17
07:22 am
zvra
Zevra Therapeutics, Inc. (NASDAQ: ZVRA) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Low
Report
Zevra Therapeutics, Inc. (NASDAQ: ZVRA) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
1/17
07:22 am
zvra
Zevra Therapeutics, Inc. (NASDAQ: ZVRA) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Low
Report
Zevra Therapeutics, Inc. (NASDAQ: ZVRA) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.